Mutations in Cytoplasmic Loops of the KCNQ1 Channel and the Risk of Life-Threatening Events
Why the study?
Does β-blocker therapy reduce the risk of aborted cardiac arrest or sudden cardiac death in patients with KCNQ1 C-loop mutations?
Population
860 patients with genetically confirmed mutations in the KCNQ1 channel (type 1 long-QT syndrome)
Comparison
β-blocker therapy vs No β-blocker therapy
Design
Cohort
Follow-up
from birth through 40 years of age
Authors
Discussion
Loading...
Member takes
Implication
May support preferential β-blocker use in KCNQ1 C-loop carriers; leaves open need for prospective validation before practice change.
Structured PICO
Does β-blocker therapy reduce the risk of aborted cardiac arrest or sudden cardiac death in patients with KCNQ1 C-loop mutations?
P
Population
860 patients with genetically confirmed mutations in the KCNQ1 channel (type 1 long-QT syndrome)
I
Intervention
β-blocker therapy
C
Comparator
No β-blocker therapy (analyzed by mutation location: C-loop vs other)
O
Outcome
Aborted cardiac arrest or sudden cardiac death from birth through 40 years of agehard clinical
Patients with KCNQ1 C-loop missense mutations have a higher risk of life-threatening events but derive a pronounced benefit from beta-blocker therapy compared to other mutation carriers.
Cite This Study
Barsheshet et al. (2012) studied this question.